Redefining Clinical Outcomes in Hemophilia: The Impact of Personalized Treatment Strategies.
Hepatitis C (HCV) infection and factor inhibitors are two major issues in managing those with hemophilia. With newer therapies, hepatitis C is curable. A new therapy for hemophilia that avoids the problem of inhibitors is now available and will likely revolutionize the treatment of this disease unti...
| Publicado en: | Journal of Managed Care Medicine Vol. 22; no. 2; pp. 65 - 70 |
|---|---|
| Autor principal: | |
| Formato: | tables/charts Journal Article |
| Publicado: |
National Association of Managed Care Physicians, Inc.
2019
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| Sumario: | Hepatitis C (HCV) infection and factor inhibitors are two major issues in managing those with hemophilia. With newer therapies, hepatitis C is curable. A new therapy for hemophilia that avoids the problem of inhibitors is now available and will likely revolutionize the treatment of this disease until a cure is found. |
|---|